| Literature DB >> 23117439 |
Robson Faria1, Leonardo Ferreira, Rômulo Bezerra, Valber Frutuoso, Luiz Alves.
Abstract
Natural products contribute significantly to available drug therapies and have been a rich source for scientific investigation. In general, due to their low cost and traditional use in some cultures, they are an object of growing interest as alternatives to synthetic drugs. With several diseases such as cancer, and inflammatory and neuropathic diseases having been linked to the participation of purinergic (P2) receptors, there has been a flurry of investigations on ligands within natural products. Thirty-four different sources of these compounds have been found so far, that have shown either agonistic or antagonistic effects on P2 receptors. Of those, nine different plant sources demonstrated effects on P2X2, P2X3, P2X7, and possibly P2Y12 receptor subtypes. Microorganisms, which represent the largest group, with 26 different sources, showed effects on both receptor subtypes, ranging from P2X1 to P2X4 and P2X7, and P2Y1, P2Y2, P2Y4, and P2Y6. In addition, there were seventeen animal sources that affected P2X7 and P2Y1 and P2Y12 receptors. Natural products have provided some fascinating new mechanisms and sources to better understand the P2 receptor antagonism. Moreover, current investigations should clarify further pharmacological mechanisms in order to consider these products as potential new medicines.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23117439 PMCID: PMC6268057 DOI: 10.3390/molecules171113009
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Natural products from plant sources.
| Compound | Receptor Type | Effects (IC50/EC50) * | Tested Model | Reference |
|---|---|---|---|---|
| Mustard oil | P2X3 | Participation in sensitization in nociceptive neurons following MO application to the tooth pulp. ND | Male Sprague-Dawley adult rats | [ |
| Sodium Ferulate | P2X3 | Decreases participation of these receptors in pain after primary sensory afferent chronic injury ND | Rat dorsal root ganglion | [ |
| Tetramethylpyrazine | P2X3 | Inhibition of depolarization, burn injury pain and neuropathic pain induced by α,β-methylene-ATP ND | Rat dorsal root ganglion | [ |
| Puerarin | P2X3 | Impairment of neuropathic pain ND | Dorsal root ganglion neurons | [ |
| Emodin | P2X2/3 | Inhibition of the transmission of neuropathic pain stimuli ND | Sprague-Dawley male rats | [ |
| Emodin | P2X7 | Inhibits ATP/BzATP-activated P2X7 receptor IC50 = 200 nM (cell death) | Rat peritoneal macrophages | [ |
| Emodin | P2X7 | Inhibits ATP/BzATP-activated P2X7 receptor IC50 = 500 nM (BzATP- and induced dye uptake) | Rat peritoneal macrophages | [ |
| Emodin | P2X7 | Inhibits ATP/BzATP-activated P2X7 receptor IC50 = 3.4 µM (BzATP-evoked current) | HEK 293 | [ |
| P2X7 | Inhibits P2X7 receptor-associated pore opening, currents and dye uptake functional assay IC50 = 2 µg/mL (functional assay) | Mouse peritoneal macrophages | [ | |
| Flavonoid molecules | P2Y2 | Potent antagonism and inhibition of intracellular calcium release ND | NG108-15 cells | [ |
| P2Y12 (?) | Inhibition of ADP-induced platelets aggregation IC50 = 1.28 mg/mL | Rabbit platelets | [ | |
| P2X | Inhibits α,β-methylene-ATP (30 µM) induced isometric contraction IC50 = 1.57 mg/mL | Mouse vas deferens | [ | |
| Colchicine | P2X7 | Inhibits P2X7 receptor-associated pore opening EC50 = 290 μM | Xenopus laevis oocytes | [ |
| Colchicine | P2X7 | Inhibits P2X7 receptor-associated pore opening EC50 = 540 μM | Peritoneal mouse macrophages | [ |
* EC50 = half maximal effective concentration; IC50 = half maximal inhibitory concentration; ND = Not Determinated; MO = Mustard oil; BzATP = 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate.
Natural products from animal sources.
| Compound | Receptor Type | Source | Effects (IC50/EC50) * | Tested Model | Reference |
|---|---|---|---|---|---|
| Halistanol sulfate | P2Y12 | Binds to P2Y12 receptor IC50 = 0.48 µM | 1321N cells | [ | |
| Sterol sulfate Sch 572423 | Binds to P2Y12 receptor IC50 = 2.2 µM | 1321N cells | [ | ||
| Iso-iantheran-A | P2Y11 |
| Activates P2Y11 receptor EC50 = 1.29 µM | 1321N1 wild-type cells | [ |
| Iso-iantheran-B | P2Y11 |
| Activates P2Y11 receptor EC50 = 0.48 µM | 1321N1 wild-type cells | [ |
| Stylissadines A | P2X7 |
| Inhibits BzATP-induced pore formation IC50 = 0.7 µM | THP-1 cells. (Human Monocytes) | [ |
| Stylissadines B | Inhibits BzATP-induced pore formation IC50 = 1.8 µM | THP-1 cells | [ | ||
| Niphatoxin C | P2X7 | Impairment of P2X7 receptor activity ND | THP-1 cells | [ | |
| LL37 | P2X7 | Human neutrophils and epithelial cells | Induces IL-1β maturation and release in LPS-primed monocytes ND | Human monocytes | [ |
| rCRAMP | P2Y |
| Induction of IL-6 expression and ERK 1/2 in glial cells, blocked by P2Y receptor antagonists ND | Rat glial cells | [ |
| CRAMP | P2X7 |
| Inhibition of all responses related to P2X7 activation ND | Peritoneal macrophages | [ |
| Cellular prion protein | P2X4 |
| Prevents and reverses Copper-inhibited ATP-evoked current EC50 = 4.6 µM | [ | |
| Melittin | P2X2/3 and P2X3 | Apitoxin (bee venom) | Antagonists of both receptor suppressed melittin-evoked persistent spontaneous nociception ND | Male Sprague-Dawley albino rats weighing 180–250 g | [ |
| Alphadefensin 1–3 | P2Y6 | Human CD14−/CD24+ cells | Inhibits M-CSF-induced differentiation of CD14−/CD24+ cells through P2Y6 receptor ND | CD14+/CD24− monocytes human cells | [ |
| Ω-Conotoxin GVIA | P2X2/3 | Inhibits P2X2/3 receptor response IC50 = 3.84 µM | Rat dorsal root ganglion neurons | [ | |
| P2X3 | Inhibits P2X3 receptor response IC50 = 21.2 nM | Rat dorsal root ganglion neurons | [ | ||
| Purotoxin-1 | P2X | Inhibition of ionic currents in the sensory neurons of rats ND | Rat dorsal root ganglion neurons | [ | |
| Purotoxin-1 | P2X3 | Potent inhibitory effects ND | Sensory neurons | [ |
* EC50 = half maximal effective concentration; IC50 = half maximal inhibitory concentration; ND = Not Determinated.
Natural products from microorganism product sources.
| Compound | Receptor Type | Source | Effects (IC50/EC50) * | Tested Model | Reference |
|---|---|---|---|---|---|
| Ivermectin | P2X4 |
| Positive allosteric effect EC50 = 250 nM | [ | |
| Ivermectin | P2X4 |
| Blockage of ethanol-inhibitory effects ND | [ | |
| Ivermectin | P2X7 |
| Positive allosteric effect EC50 = 50 nM (EC50 from high affinity-binding site) | Macrophage from humans | [ |
| Polymyxin B | P2X7 |
| Enhanced P2X7 responses in transfected-HEK293 and K562 cells ND | Mouse and human macrophage cells | [ |
| Pfiesteriatoxin | P2X7 |
| Activation of cell permeabilization similarly to ATP activation ND | GH4C1 rat pituitary cells | [ |
| Pfiesteriatoxin | P2X7 |
| Induction of toxic and c- | GH4C1 rat pituitary cells | [ |
| HlyA | P2X1 and P2X7 |
| Antagonists of both receptor blocked HlyA induced hemolysis ND | Human, mouse and equine Erythrocytes | [ |
| Cytotoxic factors | P2X7 |
| P2X7 receptor participation in ATP-dependent pathway ND | J774 macrophage cell line | [ |
| Leukotoxin | P2X7 |
| Leukotoxin-induced proinflammatory responses, release of IL-1β and IL-18 are blocked by oxATP ND | Human macrophages | [ |
| Oxo-AHL | P2Y2 and P2Y4 |
| Inhibits P2Y2 and P2Y4 expression in cystic fibrosis IC 50 = 0.3 pM | HTGS cell line MM39 | [ |
| LPS | P2X7 | Gram-negative bacteria | P2X7 receptor modulates LPS-induced responses ND | Murine Peritoneal Macrophages | [ |
| LPS | P2X7 | Gram-negative bacteria | P2X7 receptor inhibition in TLR-4-defficient cell ND | HEK293 cells | [ |
| LPS | P2Y6 | Gram-negative bacteria | Vascular inflammation following selective induction of endothelial P2Y6 receptor ND | HMEC-1 | [ |
| LOS | P2X | Gram-negative bacteria | Inhibition of P2X receptor decrease LOS-induced caspase-8 activation and apoptosis ND | Primary bovine pulmonary artery endothelial cells | [ |
* EC50 = half maximal effective concentration; IC50 = half maximal inhibitory concentration; ND = Not Determinated; LOS = Lipooligosaccharide.